SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade

Checkpoint blockade has demonstrated promising antitumor responses in approximately 10–40% of patients. However, the majority of patients do not make a productive immune response to their tumors and do not respond to checkpoint blockade. These patients may benefit from an effective vaccine that stim...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Wei, Metheringham, Rachael L., Brentville, Victoria A., Gunn, Barbara, Symonds, Peter, Yagita, Hideo, Ramage, Judith M., Durrant, Lindy G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938367/
https://www.ncbi.nlm.nih.gov/pubmed/27471648
http://dx.doi.org/10.1080/2162402X.2016.1169353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4938367/
https://www.ncbi.nlm.nih.gov/pubmed/27471648
http://dx.doi.org/10.1080/2162402X.2016.1169353

Ejemplares similares